Non-antimicrobial therapies for recurrent urinary tract infection in women: is there a place for faecal microbiota transfer?
Abstract
BACKGROUND
Recurrent urinary tract infection (rUTI) is a common condition, affecting approximately one-third of women after an initial UTI. It significantly impacts healthcare costs and patient quality of life. The relationship between the pathophysiology of UTI and the gut and vaginal microbiota is recognised as a contributing factor to rUTI in women. As antibiotic resistance among uropathogens continues to increase, there is a clear need to develop novel therapeutic interventions. Faecal microbiota transfer (FMT) is a potent non-antimicrobial strategy for modulating the gut microbiota; however, its clinical relevance in the context of rUTI is unclear.
OBJECTIVES
This narrative review aims to summarise the current evidence on the use of FMT for the treatment of rUTI, focusing in women, excluding those with mechanical dysfunctions such as urinary incontinence, neurogenic bladder, and bladder cancer, compared with other non-antimicrobial interventions. We also discuss the pathophysiology and epidemiology of rUTI to identify patients for whom microbiota-targeting therapies may be the most effective.
CONTENT
Periurethral colonization and migration to the bladder of uropathogens that inhabit the gut and vagina has been linked to the aetiology of UTI in women, particularly in patients with multidrug resistant organisms. FMT appears to be a promising approach for preventing the clinical development of rUTI, although prospective data remain limited. In contrast, other reported…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.